MAP2K7 and breast carcinoma: In contrast, human cancer cells with oncogenic KRAS mutations (HCT116 and SW620 colon cancer cells, A549 lung and MDA-MD-231 breast cancer cells) were much less sensitive to this MEK inhibition (Figure 4A; Figure S4A, Supplementary Material).